Table 3 Clinical data of controls and FCD type II patients.
Patient/Controla | Age (years) | Sex | Pathology/CODb | Antiepileptic drugsc |
|---|---|---|---|---|
A1 | 25 | M | Pelvic injury | NA |
A2 | 18 | F | Pelvic injury and lower limb injury | NA |
A3 | 16 | M | Abdominal injury | NA |
A4 | 18 | M | Head and abdominal injury | NA |
A5 | 40 | M | Respiratory failure | NA |
A6 | 36 | F | Heart failure | NA |
A7 | 26 | F | Pulmonary carcinoma | NA |
A8 | 19 | F | Renal carcinoma | NA |
A9 | 33 | M | Abdominal injury | NA |
A10 | 8 | M | Heart failure | NA |
F1 | 13 | F | FCD typeIIb | CLO, PHT, LEV |
F2 | 18 | M | FCD typeIIa | CBZ, LEV, TPR |
F3 | 24 | F | FCD typeIIb | CLN, VPA, LEV, VBN, ZNS |
F4 | 6 | M | FCD typeIIa | VPA, CLO |
F5 | 5 | F | FCD typeIIa | CBZ, CLO, LEV |
F6 | 13 | M | FCD typeIIa | CLO, CLN, LTG, LEV, VPA |
F7 | 24 | F | FCD typeIIb | LTG, VPA, TPR |
F8 | 16 | F | FCD typeIIb | VPA, LEV |
F9 | 28 | M | FCD typeIIb | CBZ, CLO |
F10 | 38 | M | FCD typeIIa | CLO, PHT, LEV |
